{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:29:32Z","timestamp":1785266972162,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.cmi.2018.03.022","type":"journal-article","created":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T23:53:24Z","timestamp":1521590004000},"page":"S83-S94","source":"Crossref","is-referenced-by-count":97,"special_numbering":"S2","title":["ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4)"],"prefix":"10.1016","volume":"24","author":[{"given":"L.","family":"Drgona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Salzberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ippolito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2018.03.022_bib1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.cmi.2018.01.029","article-title":"ESCMID study group for infections in compromised hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (introduction)","volume":"24","author":"Fern\u00e1ndez-Ruiz","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2018.03.022_bib2","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.03.022_bib3","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cmi.2018.03.022_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2013unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.03.022_bib5","first-page":"701493","article-title":"Target therapy in hematological malignances: new monoclonal antibodies","volume":"2014","author":"Podhorecka","year":"2014","journal-title":"Int Sch Res Not"},{"key":"10.1016\/j.cmi.2018.03.022_bib6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/art.39856","article-title":"Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase iii randomized, double-blind, placebo-controlled trials","volume":"69","author":"Clowse","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cmi.2018.03.022_bib7","article-title":"Epratuzumab: targeting B-cell malignancies through CD22","volume":"9","author":"Coleman","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2018.03.022_bib8","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2017.1366447","article-title":"Emerging antibody-drug conjugates for treating lymphoid malignancies","volume":"22","author":"Wolska-Washer","year":"2017","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.cmi.2018.03.022_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/14737140.2016.1131614","article-title":"Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia","volume":"16","author":"Morley","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.cmi.2018.03.022_bib10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.beha.2015.09.003","article-title":"Immunoconjugates in the management of hairy cell leukemia","volume":"28","author":"Kreitman","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.cmi.2018.03.022_bib11","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/cncr.23890","article-title":"Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma","volume":"113","author":"Leonard","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.03.022_bib12","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2006.05.6291","article-title":"Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma","volume":"24","author":"Strauss","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib13","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","article-title":"Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study","volume":"28","author":"Advani","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib14","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2012.42.7211","article-title":"Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab","volume":"31","author":"Fayad","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.03.022_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/rheumatology\/ket129","article-title":"Efficacy and safety of epratuzumab in patients with moderate\/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up","volume":"52","author":"Wallace","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cmi.2018.03.022_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.12778","article-title":"SWOG S0910: a phase 2 trial of clofarabine\/cytarabine\/epratuzumab for relapsed\/refractory acute lymphocytic leukaemia","volume":"165","author":"Advani","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.03.022_bib18","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1002\/cncr.28299","article-title":"A\u00a0phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701","volume":"119","author":"Grant","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2018.03.022_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/pbc.25454","article-title":"Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): phase II results from Children's Oncology Group (COG) study ADVL04P2","volume":"62","author":"Raetz","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2018.03.022_bib20","series-title":"Brentuximab vedotin","first-page":"85","volume":"vol. 11","year":"2011"},{"key":"10.1016\/j.cmi.2018.03.022_bib21","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0092-8674(93)90361-S","article-title":"CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF","volume":"73","author":"Smith","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.cmi.2018.03.022_bib22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jlb.57.5.726","article-title":"CD30 and type 2 T helper (Th2) responses","volume":"57","author":"Romagnani","year":"1995","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.cmi.2018.03.022_bib23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/intimm\/13.3.341","article-title":"Induction of type 2 activity in adult human CD8(+) T cells by repeated stimulation and IL-4","volume":"13","author":"Stanciu","year":"2001","journal-title":"Int Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib24","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib25","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib26","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.03.022_bib27","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3109\/10428194.2012.676170","article-title":"Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin","volume":"53","author":"Wagner-Johnston","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.03.022_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.clineuro.2012.03.019","article-title":"Brentuximab associated progressive multifocal leukoencephalopathy","volume":"114","author":"Jalan","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.cmi.2018.03.022_bib29","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1212\/WNL.0b013e3182749f17","article-title":"PML-IRIS in a patient treated with brentuximab","volume":"79","author":"von Geldern","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.cmi.2018.03.022_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx091","article-title":"Cytomegalovirus infection with retinitis after brentuximab vedotin treatment for CD30+ lymphoma","volume":"4","author":"Tudesq","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2018.03.022_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2018.03.022_bib32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.cmi.2018.03.022_bib33","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib34","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/2159-8290.CD-NB2017-132","article-title":"Gemtuzumab ozogamicin makes a comeback","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cmi.2018.03.022_bib35","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib36","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2013.49.0771","article-title":"Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17)","volume":"31","author":"Amadori","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib37","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2018.03.022_bib38","first-page":"636","article-title":"Progressive multifocal leukoencephalopathy in a patient with acute myeloid leukaemia after allogeneic hematopoietic-cell transplantation","volume":"29","author":"Fernandez-Ruiz","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.cmi.2018.03.022_bib39","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"van de Donk","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.cmi.2018.03.022_bib40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.03.022_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.03.022_bib43","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.03.022_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cmi.2018.03.022_bib45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V126.23.509.509","article-title":"A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed\/refractory multiple myeloma","volume":"126","author":"Martin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib46","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2016-09-740787","article-title":"A\u00a0Phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"van de Donk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib48","first-page":"31","article-title":"New developments in the treatment of multiple myeloma\u2014clinical utility of daratumumab","volume":"11","author":"McEllistrim","year":"2017","journal-title":"Biologics"},{"key":"10.1016\/j.cmi.2018.03.022_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.20132","article-title":"Immunotherapy of cancer in 2012","volume":"62","author":"Kirkwood","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cmi.2018.03.022_bib50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12016-013-8378-7","article-title":"The hyper IgM syndromes","volume":"46","author":"Qamar","year":"2014","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib51","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s10875-013-9951-9","article-title":"Clinical, immunological, and molecular characterization of hyper-IgM syndrome due to CD40 deficiency in eleven patients","volume":"33","author":"Al-Saud","year":"2013","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s10875-016-0291-4","article-title":"Hyper IgM syndrome: a report from the USIDNET registry","volume":"36","author":"Leven","year":"2016","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s10875-013-9980-4","article-title":"First report of the Hyper-IgM syndrome Registry of the Latin American Society for Immunodeficiencies: novel mutations, unique infections, and outcomes","volume":"34","author":"Cabral-Marques","year":"2014","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib54","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.3109\/10428194.2015.1007504","volume":"56","author":"Fayad","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cmi.2018.03.022_bib55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1182\/blood-2011-06-360552","article-title":"A\u00a0phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma","volume":"120","author":"Zonder","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib57","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib58","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2018.03.022_bib60","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib61","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cmi.2018.03.022_bib62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/bjh.14263","article-title":"Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed\/refractory multiple myeloma","volume":"175","author":"Mateos","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.03.022_bib63","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cmi.2018.03.022_bib64","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib65","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2018.03.022_bib66","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbmt.2016.05.017","article-title":"Mogamulizumab treatment prior to allogeneic hematopoietic stem cell transplantation induces severe acute graft-versus-host disease","volume":"22","author":"Sugio","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.cmi.2018.03.022_bib67","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int Immunol"},{"key":"10.1016\/j.cmi.2018.03.022_bib68","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib69","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cmi.2018.03.022_bib70","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cmi.2018.03.022_bib71","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","article-title":"European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2018.03.022_bib72","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12185-015-1750-z","article-title":"Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy","volume":"101","author":"Totani","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.cmi.2018.03.022_bib73","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hepr.12117","article-title":"Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"44","author":"Nakano","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cmi.2018.03.022_bib74","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/hepr.12513","article-title":"Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"45","author":"Ifuku","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cmi.2018.03.022_bib75","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jiac.2015.07.001","article-title":"Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia-lymphoma treated with mogamulizumab","volume":"21","author":"Tamaki","year":"2015","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.cmi.2018.03.022_bib76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hemonc.2016.04.004","article-title":"Disseminated Mycobacterium chelonae infection in a patient with T-cell lymphoma","volume":"10","author":"van der Wekken","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18302325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X18302325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T06:05:42Z","timestamp":1657433142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X18302325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":76,"alternative-id":["S1198743X18302325"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2018.03.022","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}